Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7269162 in Prodromal or Preclinical Alzheimer's Disease
NCT06402838Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- May 2024
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of nivegacetor in Alzheimer's disease (AD), sponsored by Roche. Started May 2024; status: active, not recruiting.
02
Drugs
nivegacetor
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06402838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06402838.